Stryker Corporation Reports 2.6% Net Sales Increase to $6.02 Billion in Q1 2026

Stryker Corporation reported a net sales increase of 2.6% for the first quarter of 2026, reaching $6.02 billion compared to $5.87 billion in the same period last year. The company's gross profit also rose to $3.81 billion, up from $3.74 billion, although the gross profit margin slightly decreased to 63.3% from 63.8%. Net earnings for the quarter were $745 million, or $1.93 per diluted share, reflecting a 13.9% increase in net earnings compared to $654 million, or $1.69 per diluted share, in the prior year.

The company experienced notable changes in its operational structure, announcing a reorganization that created a new business segment called Ortho Tech. This segment combines the orthopaedic instruments portfolio with the Mako and enabling technologies portfolio, aimed at enhancing customer experience and accelerating innovation. The reorganization has been reflected in the financial statements, with historical segment data adjusted accordingly. Additionally, Stryker's total operating income increased to $936 million from $837 million, resulting in an operating income margin of 15.5%.

In terms of operational metrics, Stryker's MedSurg and Neurotechnology segment saw a 5.0% increase in net sales, while the Orthopaedics segment reported a marginal increase of 0.1%. The company noted that unit volume growth contributed positively to sales, particularly in the Instruments and Vascular businesses. However, the Orthopaedics segment faced challenges, with a decrease in sales for spinal implants. The company also reported a decrease in selling, general, and administrative expenses, which fell to 37.9% of net sales from 39.2% in the previous year, primarily due to disciplined spending and lower acquisition-related charges.

Looking ahead, Stryker remains focused on maintaining its growth trajectory despite potential challenges posed by macroeconomic conditions, including inflation and geopolitical tensions. The company is committed to its long-term capital allocation strategy, which prioritizes acquisitions, dividends, and share repurchases. Stryker's management expressed confidence in its ability to navigate these challenges while continuing to innovate and expand its product offerings in the medical technology sector.